44 THERAPEUTIC DRUG MONITORING
Johannessen SI, Tomson T. Pharmacokinetic variability of newer
antiepileptic drugs – When is monitoring needed? Clinical
Pharmacokinetics2006; 45 : 1061–75.
Kaplan B. Mycophenolic acid trough level monitoring in solid organ
transplant recipients treated with mycophenolate mofetil: associ-
ation with clinical outcome. Current Medical Research and Opinion
2006; 22 : 2355–64.
Mitchell PB. Therapeutic drug monitoring of psychotropic medica-
tions.British Journal of Clinical Pharmacology2000; 49 : 303–12.
Oellerich M, Armstrong VW. The role of therapeutic drug monitoring
in individualizing immunosuppressive drug therapy: Recent
developments.Therapeutic Drug Monitoring2006; 28 : 720–25.
Stamp L, Roberts R, Kennedy M, Barclay M, O’Donnell J, Chapman P.
The use of low dose methotrexate in rheumatoid arthritis – are we
entering a new era of therapeutic drug monitoring and pharma-
cogenomics?Biomedicine and Pharmacotherapy2006; 60 : 678–87.FURTHER READING
Arns W, Cibrik DM, Walker RG et al. Therapeutic drug monitoring of
mycophenolic acid in solid organ transplant patients treated with
mycophenolate mofetil: Review of the literature. Transplantation
2006; 82 : 1004–12.
Aronson JK, Hardman M, Reynolds DJM. ABC of monitoring drug
therapy. London: BMJ Publications, 1993.
Bartelink IH, Rademaker CMA, Schobben AFAM et al. Guidelines on
paediatric dosing on the basis of developmental physiology and
pharmacokinetic considerations. Clinical Pharmacokinetics2006;
45 : 1077–97.
Fleming J, Chetty M. Therapeutic monitoring of valproate in psychia-
try: How far have we progressed? Clinical Neuropharmacology2006;
29 : 350–60.
Herxheimer A. Clinical pharmacology and therapeutics. In: Warrell
DA (ed.). Oxford textbook of medicine, 4th edn. Oxford: Oxford
University Press, 2006.